Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

Dong W. Kim, Kwangzoo Chung, Weon K. Chung, Sun H. Bae, Dong O. Shin, Seongeon Hong, Sung H. Park, Sung Yong Park, Chae Seon Hong, Young K. Lim, Dongho Shin, Se B. Lee, Hyun ho Lee, Jiwon Sung, Myonggeun Yoon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

Original languageEnglish
Article number109
JournalRadiation Oncology
Volume9
Issue number1
DOIs
Publication statusPublished - 2014 May 8

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Kim, D. W., Chung, K., Chung, W. K., Bae, S. H., Shin, D. O., Hong, S., Park, S. H., Park, S. Y., Hong, C. S., Lim, Y. K., Shin, D., Lee, S. B., Lee, H. H., Sung, J., & Yoon, M. (2014). Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. Radiation Oncology, 9(1), [109]. https://doi.org/10.1186/1748-717X-9-109